ArchPoint Investors’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

ArchPoint Investors’s Portfolio LABP Stock Details LABP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12,726	Closed	-$83K	–	63
2022 Q3	$83K	Hold	12,726	–	–	0.03%	57
2022 Q2	$93K	Sell	12,726 -149	-1%	-$1.35K	0.04%	54
2022 Q1	$190K	Hold	12,875	–	–	0.07%	55
2021 Q4	$618K	Hold	12,875	–	–	0.18%	49
2021 Q3	$1.88M	Buy	12,875 +597	+5%	+$77.5K	0.56%	31
2021 Q2	$1.42M	Buy	12,278 +2,530	+26%	+$282K	0.48%	30
2021 Q1	$939K	Buy	+9,748	New	+$1.27M	0.27%	59

Other funds holding LABP

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

SGCA

Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ArchPoint Investors's LABP Position: Q4 2022 in Review

ArchPoint Investors sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q4 2022, closing a stake of 12,726 shares — an estimated $83K sold.

ArchPoint Investors first reported a position in LABP in Q1 2021 and held it in 7 quarters. The position peaked at $1.88M in Q3 2021. 23 funds tracked by Wall St. Rank hold LABP as of Q4 2022.

ArchPoint Investors reported no remaining Landos Biopharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
ArchPoint Investors sold 12,726 Landos Biopharma, Inc. Common Stock shares in Q4 2022, an estimated $83K.
ArchPoint Investors first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
ArchPoint Investors's Landos Biopharma, Inc. Common Stock position peaked at $1.88M in Q3 2021.
23 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q4 2022.

Based on ArchPoint Investors's 13F filing for Q4 2022, filed 13 Feb 2023.